Braedstrup, Denmark
- Featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**
Phase
3Span
Sponsor
Hiroshima, Hiroshima
Recruiting
Hiroshima
Recruiting
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
Phase
2Span
234 weeksSponsor
Novo Nordisk A/SHiroshima
Recruiting
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Phase
3Span
88 weeksSponsor
AbbVieHiroshima
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Phase
3Span
122 weeksSponsor
SanofiHiroshima
Recruiting
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Phase
2Span
134 weeksSponsor
Kowa Research Institute, Inc.Hiroshima
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Phase
3Span
365 weeksSponsor
Merck Sharp & Dohme LLCHiroshima
Recruiting
Hiroshima
Recruiting
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Participants will be randomized 1:1 into two arms: - Sacituzumab tirumotecan - Pemetrexed plus Carboplatin Participants will receive treatment until any of the criteria for discontinuation of study intervention are met.
Phase
3Span
314 weeksSponsor
Merck Sharp & Dohme LLCHiroshima
Recruiting
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Phase
N/ASpan
203 weeksSponsor
Eisai Co., Ltd.Hiroshima
Recruiting
1-10 of 96